A Phase II Study of Romidepsin after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma


Full Title

A Phase 2 Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T cell Non-Hodgkin Lymphoma


Using a patient’s own cells (special cells called “stem cells”) to help increase blood counts after high doses of chemotherapy is called autologous stem cell transplantation (ASCT). ASCT is a treatment approach used for patients with T-cell non-Hodgkin lymphoma (NHL).

Romidepsin is a drug approved by the U.S. Food and Drug Administration for patients with T-cell NHL whose cancer has returned following therapy. In this study, researchers are seeking to determine if romidepsin is effective for preventing or delaying the return of T-cell NHL after a patient has had high-dose chemotherapy and ASCT. Romidepsin is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have T-cell NHL and be planning to have high-dose chemotherapy and ASCT.
  • Patients may not have received prior romidepsin therapy nor had ASCT or an allogeneic (donated) transplant.
  • This study is open to patients age 16 to 70.

For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.